Your browser doesn't support javascript.
loading
prognostic value of triple negative in stage II/III breast cancer
Assiut Medical Journal. 2010; 34 (3): 99-110
in English | IMEMR | ID: emr-110715
ABSTRACT
Breast cancer is no longer seen as a single disease but rather a multifaceted disease composed of distinct biological subtypes with diverse natural history, clinical, pathological and molecular features. Recent attention has been directed at molecular classification of breast cancer. To evaluate the prognostic value of triple negative subtype in stage II/III breast cancer. To define the role of clinical stage in pro gnosis of breast cancer We used immuno-histochemical technique to divide 255 cases of breast cancer, stages II and III, into four subtypes according to estrogen receptor/progesterone receptor [ER/PR] and Her-2 expression. Triple-negative subtype comprised 76.5% of the cases with 12.3% recurrence rate. Luminal A subtype also carried a poor out come with 16. 7% recurrence rate. Triple negative subtype has the worst overall and disease-free survival in stage II/III breast cancer. Clinical stage is still an independent prognostic factor in breast cancer of all types
Subject(s)
Search on Google
Index: IMEMR (Eastern Mediterranean) Main subject: Prognosis / Immunohistochemistry / Chemotherapy, Adjuvant / Neoplasm Staging Limits: Female / Humans Language: English Journal: Assiut Med. J. Year: 2010

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Index: IMEMR (Eastern Mediterranean) Main subject: Prognosis / Immunohistochemistry / Chemotherapy, Adjuvant / Neoplasm Staging Limits: Female / Humans Language: English Journal: Assiut Med. J. Year: 2010